Brief: Summit Therapeutics Announces Completion Of Enrollment In Phase III HARMONI Trial In 2L+ EGFRM NSCLC
03/10/2024 21:45
Oct 3 (Reuters) - Summit Therapeutics Inc SMMT.O :
* SUMMIT THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
ITS
PHASE III HARMONI TRIAL IN 2L+ EGFRM NSCLC
* SUMMIT THERAPEUTICS INC - TOPLINE DATA FROM HARMONI TRIAL
EXPECTED IN MID-2025
Source text for Eikon: ID:nBw8MYMP2a
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering